T1	Treatment 0 29	Low-dose oral etoposide-based
T2	Treatment 164 182	low-dose etoposide
T3	Treatment 338 383	epipodophyllotoxins during frontline therapy.
T4	Treatment 434 541	patients received etoposide (50 mg/m(2) per day) administered orally as a single agent once or twice daily.
T5	Treatment 580 627	dexamethasone, vincristine, and L-asparaginase.
T6	Treatment 628 668	Etoposide was administered until Day 22.
T7	Treatment 669 787	Two courses of consolidation therapy were followed by continuation therapy or hematopoietic stem cell transplantation.
T8	Treatment 1230 1248	low-dose etoposide
